Improvements in cough frequency over 24 hours with BLU-5937, a selective P2X3 antagonist, in patient subgroups defined by baseline awake cough frequencies

This analysis examined the efficacy and safety of BLU-5937 according to baseline awake cough frequency in 69 patients with refractory chronic cough who participated in a proof-of-concept, Phase IIa, dose-escalation, two-period crossover study. Cough frequency was measured over a 24-hour period using the Vitalograph VitaloJAK cough recorder.